38 results on '"Mitsudomi, T."'
Search Results
2. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
3. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials
4. Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth
5. 932MO Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816
6. 931MO Final overall survival analysis of phase III study of pemetrexed/cisplatin versus vinorelbine/cisplatin for completely resected non-squamous non-small cell lung cancer: The JIPANG Study
7. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
8. S-1 as an option for second-line treatment of NSCLC. Is the ‘East Side Story’ applicable in the West?
9. An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting
10. Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer
11. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
12. An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer
13. 1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial
14. LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial
15. LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression
16. Latest innovations in NSCLC management
17. Testing for COVID-19 in lung cancer patients
18. JIPANG study: Randomized phase III study of pemetrexed/cisplatin (PEM/Cis) versus vinorelbine /cisplatin (VNR/Cis) for completely resected p-stage II-IIIA non-squamous non-small cell lung cancer (Ns-NSCLC): Outcomes based on EGFR mutation status
19. Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies
20. 1440PD - JIPANG study: Randomized phase III study of pemetrexed/cisplatin (PEM/Cis) versus vinorelbine /cisplatin (VNR/Cis) for completely resected p-stage II-IIIA non-squamous non-small cell lung cancer (Ns-NSCLC): Outcomes based on EGFR mutation status
21. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
22. Adjusted indirect comparison using propensity score matching of osimertinib to doublet chemotherapy in patients with EGFRm T790M NSCLC who have progressed after EGFR-TKI
23. 1348P - Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies
24. Magrit, a Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of the Recmage-A3 + As15 Cancer Immunotherapeutic As Adjuvant Therapy in Patients with Resected Mage-A3-Positive Non-Small Cell Lung Cancer (Nsclc)
25. Antitumor Activity of Bevacizumab Combined with Erlotinib in T790M Resistance Mutation Positive Non-Small Cell Lung Cancer Xenograft Models
26. 1246P - Adjusted indirect comparison using propensity score matching of osimertinib to doublet chemotherapy in patients with EGFRm T790M NSCLC who have progressed after EGFR-TKI
27. Biomarker Analysis of WJOG4107 (A Randomized Phase II Trial of Adjuvant Chemotherapy with S-1 vs CDDP + S-1 in NSCLC)
28. Time to first cigarette and lung cancer risk in Japan
29. Vinorelbine Plus Cisplatin Versus Gefitinib in Resected Non-Small-Cell Lung Cancer Haboring Activating EGFR Mutation (WJOG6410L)
30. Biomarker Research in Lung Cancer and its Future in Japan
31. Attention Study: Asian Trial of Tivantinib Plus Erlotinib Versus Erlotinib for NSCLC without EGFR Mutation; a Phase 3 Trial with a Personalized Dose Setting Based on Pretreatment Test for CYP2C19 Polymorphism
32. Personalized Therapy and Bio-Molecular Driven Treatment in Lung Cancer
33. Analysis of EML4-ALK Positive Non-Small Cell Lung Cancer with Advanced Stage
34. 1207P - Antitumor Activity of Bevacizumab Combined with Erlotinib in T790M Resistance Mutation Positive Non-Small Cell Lung Cancer Xenograft Models
35. 1173O - Magrit, a Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of the Recmage-A3 + As15 Cancer Immunotherapeutic As Adjuvant Therapy in Patients with Resected Mage-A3-Positive Non-Small Cell Lung Cancer (Nsclc)
36. p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival
37. O3–096BIOMARKER ANALYSIS OF WJOG4107 (A RANDOMIZED PHASE II TRIAL OF ADJUVANT CHEMOTHERAPY WITH S-1 VS CDDP + S-1 IN NSCLC).
38. An activating ALK gene mutation in ALK IHC-positive/FISHnegative nonsmall-cell lung cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.